Back to results
US 2024/0254253 A1Published application
ANTI-uPAR ANTIBODIES AND USES THEREOF
AssigneesMemorial Sloan Kettering Cancer Center, Sloan-Kettering Institute for Cancer Research, Memorial Hospital for Cancer and Allied Diseases, Tri-Institutional Therapelitics Discovery Institute, Inc.
InventorsScott W. Lowe, Michel Sadelain, Corina Amor Vegas, Paul Balderes, Ivo C. Lorenz
Life of this patent
Estimating the term…
Abstract
The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that bind to uPAR and methods of using such antibodies or antigen-binding fragments thereof same.
Claims30
An anti-uPAR antibody or an antigen-binding fragment thereof, comprising:
- (a) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 1, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO 2, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO;
- 3;
- and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 4, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 5, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 6;
- (b) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 11, a CDR2 comprising an amino acid sequence set forth in SEQ ID NO:
- 2, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 12;
- and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 13, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 5, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 14;
- (c) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 19, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 2, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 20;
- and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 21, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 5, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 22;
- (d) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 19, a (CDR2 comprising the anno acid sequence set forth in SEQ ID NO:
- 27, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 28;
- and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 29, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 5, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 30;
- (e) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 35, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 36, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 37;
- and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 38, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 39, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 40;
- (f) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 45, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 46, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 47;
- and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 48, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 5, and a CDR3 comprising the amino acid sequence set forth in SEQ) ID NO:
- 49;
- (g) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 54, a comprising the amino acid sequence set forth in SEQ ID NO:
- 55, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 56;
- and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 57, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 5, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 58;
- (h) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 63, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 64, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 65;
- and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 66, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 67, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 68;
- (i) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 73, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 74, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 5 and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 76, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 67, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 77;
- (j) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 45, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 82, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 83;
- and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 84, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 67, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 85;
- (k) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 0, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 91, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 92;
- and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 93, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 67, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 94;
- or
- (l) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 45, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 46, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 99;
- and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 66, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 67, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 100.
92 more elements
Dependencies are inferred from the claim text.